IN2014DN03485A - - Google Patents

Download PDF

Info

Publication number
IN2014DN03485A
IN2014DN03485A IN3485DEN2014A IN2014DN03485A IN 2014DN03485 A IN2014DN03485 A IN 2014DN03485A IN 3485DEN2014 A IN3485DEN2014 A IN 3485DEN2014A IN 2014DN03485 A IN2014DN03485 A IN 2014DN03485A
Authority
IN
India
Prior art keywords
nanoparticles
cancer
quillaja
treatment
phospholipid
Prior art date
Application number
Inventor
Bror Morein
Saideh Berenjian
Kafei Hu
Original Assignee
Moreinx Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47143250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN03485(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Moreinx Ab filed Critical Moreinx Ab
Publication of IN2014DN03485A publication Critical patent/IN2014DN03485A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Nanotechnology (AREA)

Abstract

The present invention regards nanoparticles comprising a sterol and a component derived from Quillaja saponaria Molina selected from quillaja acid and quillaja saponin which nanoparticles do not comprise a phospholipid. It also relates to a composition comprising the nanoparticles and the use thereof as adjuvant especially in vaccines as carriers for amphipathic or hydrophobic molecules and as agents for treatment of cancer. Further it regards a method for producing the phospholipid free nanoparticles a method for the treatment of cancer and a method for assessing the applicability of the cancer treating method.
IN3485DEN2014 2011-10-03 2012-10-01 IN2014DN03485A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161542425P 2011-10-03 2011-10-03
PCT/SE2012/051048 WO2013051994A1 (en) 2011-10-03 2012-10-01 Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds

Publications (1)

Publication Number Publication Date
IN2014DN03485A true IN2014DN03485A (en) 2015-06-05

Family

ID=47143250

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3485DEN2014 IN2014DN03485A (en) 2011-10-03 2012-10-01

Country Status (17)

Country Link
US (3) US10047116B2 (en)
EP (3) EP4176871A1 (en)
JP (1) JP6050822B2 (en)
KR (1) KR102090740B1 (en)
CN (1) CN103857403B (en)
AU (1) AU2012319239B2 (en)
CA (1) CA2850296C (en)
DK (2) DK3311827T3 (en)
ES (1) ES2673957T5 (en)
HR (1) HRP20180956T1 (en)
IN (1) IN2014DN03485A (en)
PL (1) PL2750683T3 (en)
PT (1) PT2750683T (en)
RS (1) RS57350B1 (en)
TR (1) TR201808733T4 (en)
WO (1) WO2013051994A1 (en)
ZA (1) ZA201402040B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6050822B2 (en) 2011-10-03 2016-12-21 モレインクス，エービー Use of nanoparticles as carriers for amphipathic or hydrophobic molecules in the medical field including nanoparticles, treatments for the preparation of nanoparticles, and cancer treatment and food-related compounds
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
EP2777402A1 (en) * 2013-03-15 2014-09-17 DSM IP Assets B.V. Solid lipid nanoparticles (I)
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
CN104382856B (en) * 2014-12-04 2017-11-14 中国药科大学 A kind of deoxypodophyllotoxin long circulating liposome lyophilized formulations
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
CN110494543A (en) 2016-10-19 2019-11-22 弗洛设计声能学公司 Pass through the affine cell extraction of acoustics
US11478433B2 (en) 2017-06-23 2022-10-25 Yale University Nanomaterials with enhanced drug delivery efficiency
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
EP3669890A1 (en) * 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
JP7597554B2 (en) * 2020-10-30 2024-12-10 株式会社ニップン Oxytocin receptor agonist composition
CN116077639A (en) * 2023-01-05 2023-05-09 国药中生生物技术研究院有限公司 Application of tripterine or medicinal derivative thereof in preparation of vaccine adjuvant

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US3046301A (en) 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil
US3803124A (en) 1968-04-12 1974-04-09 Farmaceutici It Soc Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives
GB1235022A (en) 1969-06-04 1971-06-09 Laeaeke Ag A new method for the production of cyclophosphamide
DE2124023C3 (en) 1970-05-27 1980-07-10 Richter Gedeon Vegyeszeti Gyar R.T., Budapest Process for the selective extraction of vinblastine, vinleurosine and vincristine or their sulfates
US4020270A (en) 1974-05-02 1977-04-26 Societa' Farmaceutici Italia S.P.A. L-lyxohex-1-enopyranose derivative
GB1467383A (en) 1974-06-12 1977-03-16 Farmaceutici Italia Daunomycin analogues
US4307100A (en) 1978-08-24 1981-12-22 Agence Nationale De Valorisation De La Recherche (Anvar) Nor bis-indole compounds usable as medicaments
DE2845574A1 (en) 1978-10-19 1980-04-24 Deutsches Krebsforsch CCNU SUBSTITUTED ANALOGS BY HETEROCYCLIC RINGS OR ALKYL RESIDUES AND METHOD FOR THE PRODUCTION THEREOF
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
EP0111058B1 (en) 1982-11-26 1987-11-04 Nippon Kayaku Kabushiki Kaisha Process for producing 4'-demethyl-epipodophyllotoxin-beta-d-ethylidene-glucoside and acyl-derivative thereof
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS6019790A (en) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd Novel camptothecin derivative
SE8405493D0 (en) 1984-11-01 1984-11-01 Bror Morein IMMUNOGENT COMPLEX AND KITCHEN FOR PREPARING IT AND USING IT AS IMMUNOSTIMENTING AGENTS
ATE71303T1 (en) * 1986-01-14 1992-01-15 Nederlanden Staat PROCESS FOR THE PREPARATION OF IMMUNOLOGICAL COMPLEXES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
FR2601676B1 (en) 1986-07-17 1988-09-23 Rhone Poulenc Sante PROCESS FOR THE PREPARATION OF TAXOL AND DESACETYL-10 TAXOL
FR2601675B1 (en) 1986-07-17 1988-09-23 Rhone Poulenc Sante TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH0679958B2 (en) 1988-10-07 1994-10-12 東レ株式会社 Yarn winding device
GB8919819D0 (en) 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
NL9002314A (en) * 1990-10-23 1992-05-18 Nederlanden Staat IMMUNOGENE COMPLEXES, IN PARTICULAR ISCOMS.
MX9102128A (en) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa DERIVATIVES OF TAXANE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM
SE502569C2 (en) * 1991-05-31 1995-11-13 British Tech Group Use of an immunologically inert matrix of a sterol and saponins which can form spherical nanoparticles of narrow size distribution such as drug carriers, particles, composition and kits
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE255131T1 (en) 1991-06-14 2003-12-15 Genentech Inc HUMANIZED HEREGULIN ANTIBODIES
IT1250692B (en) 1991-07-23 1995-04-21 PROCEDURE FOR THE PREPARATION OF DEMETYLEPIPODOPHYLOTOXY-BETA-D-GLUCOSIDES.
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5476932A (en) 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US20010053365A1 (en) * 1995-04-25 2001-12-20 Smithkline Beecham Biologicals S.A. Vaccines
SE9600647D0 (en) 1996-02-21 1996-02-21 Bror Morein New use
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9719426D0 (en) 1997-09-13 1997-11-12 Johnson Matthey Plc Novel process
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE59903869D1 (en) * 1998-10-14 2003-01-30 Cognis Deutschland Gmbh USE OF NANOSCALE STEROLS AND STEROLESTERS
CN1254541C (en) * 2000-02-23 2006-05-03 史密丝克莱恩比彻姆生物有限公司 new compound
DK1377320T3 (en) 2001-04-04 2009-02-09 Nordic Vaccine Technology As Polynucleotide binding complexes comprising sterols and saponins
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
JP2005500293A (en) * 2001-06-15 2005-01-06 コーナーストーン ファーマシューティカルズ Pharmaceutical compositions and diagnostic compositions comprising nanoparticles useful for the treatment of targeted tissues and cells
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
EP1465598A4 (en) * 2001-12-21 2006-12-20 David S Soane USE OF OLIGOMERS AND POLYMERS FOR SOLUBILIZING, STABILIZING AND DISPENSING A MEDICINAL PRODUCT
US6861410B1 (en) * 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
SE0202110D0 (en) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
DK1545605T3 (en) 2002-10-02 2010-04-12 Nordic Vaccine As Composition for vaccination
SE0301998D0 (en) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
US20050175623A1 (en) * 2004-02-10 2005-08-11 Zheng-Pin Wang Saponins as anticancer agent
JP2008539255A (en) * 2005-04-26 2008-11-13 マイクロビア インコーポレーテッド 4-Bialyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia
KR100641060B1 (en) * 2005-07-22 2006-11-01 삼성전자주식회사 Method for manufacturing gate structure and method for manufacturing semiconductor device using same
DE102006007903A1 (en) 2005-12-21 2007-07-05 VD-Werkstätten GmbH & Co KG Process for the production of furniture moldings
US20100221345A1 (en) * 2006-01-18 2010-09-02 National University Corporation Tokyo Medical And Osteogenic biomaterial containing osteogenesis promoting substance and nanogel
ES2630205T3 (en) * 2006-11-20 2017-08-18 Duecom Use of lipid-containing particles comprising quillaja saponins for cancer treatment
WO2008070538A2 (en) * 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
US8252555B2 (en) * 2006-12-29 2012-08-28 Evonik Degussa Ag Nucleic acid encoding a cobalamin-dependent methionine synthase polypeptide
US20080299177A1 (en) * 2007-06-06 2008-12-04 Biovaluation & Analysis, Inc. Supramolecular Complexes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
CA2917512C (en) * 2007-10-12 2025-08-05 President And Fellows Of Harvard College Vaccine nanotechnology
JP2011500514A (en) * 2007-10-12 2011-01-06 シーエスエル、リミテッド Methods for raising an immune response against pandemic influenza virus
WO2009156960A2 (en) * 2008-06-27 2009-12-30 Pfizer Inc. Novel adjuvant compositions
MX2011002267A (en) * 2008-08-28 2011-03-30 Glaxosmithkline Biolog Sa Vaccine.
JP5344558B2 (en) * 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 Mucosal vaccine using cationic nanogel
MX2012000036A (en) * 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vaccine.
DK2445526T3 (en) * 2009-06-24 2016-06-27 Glaxosmithkline Biologicals Sa Recombinant RSV antigens.
CA2766285A1 (en) 2009-07-10 2011-01-13 Isconova Ab New composition
PT2670432T (en) * 2011-02-04 2021-05-04 Zoetis Services Llc Immunogenic bordetella bronchiseptica compositions
EP2709590A4 (en) * 2011-05-11 2015-05-13 Nanovalent Pharmaceuticals Inc INCREASED INHIBITION OF OSTEOSARCOME GROWTH BY CYTOTOXIC POLYMERIZED LIPOSOMAL NANOPARTICLES TARGETING THE ALKAM CELL SURFACE RECEPTOR
JP6050822B2 (en) 2011-10-03 2016-12-21 モレインクス，エービー Use of nanoparticles as carriers for amphipathic or hydrophobic molecules in the medical field including nanoparticles, treatments for the preparation of nanoparticles, and cancer treatment and food-related compounds
GB201119999D0 (en) * 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
US11390483B2 (en) 2017-10-20 2022-07-19 Corelex Shin-Ei Co., Ltd. Log roll manufacturing apparatus

Also Published As

Publication number Publication date
PT2750683T (en) 2018-06-26
JP6050822B2 (en) 2016-12-21
EP2750683A1 (en) 2014-07-09
EP2750683B2 (en) 2021-01-06
EP4176871A1 (en) 2023-05-10
KR20140084113A (en) 2014-07-04
HRP20180956T1 (en) 2018-08-24
EP2750683B1 (en) 2018-03-21
EP3311827A1 (en) 2018-04-25
RS57350B1 (en) 2018-08-31
ES2673957T5 (en) 2021-12-15
US20180327443A1 (en) 2018-11-15
KR102090740B1 (en) 2020-03-18
PL2750683T3 (en) 2018-10-31
TR201808733T4 (en) 2018-07-23
US10100078B2 (en) 2018-10-16
US20170260224A1 (en) 2017-09-14
CA2850296C (en) 2021-01-12
CN103857403A (en) 2014-06-11
DK3311827T3 (en) 2023-04-03
JP2014530219A (en) 2014-11-17
DK2750683T3 (en) 2018-07-02
CN103857403B (en) 2019-04-12
DK2750683T4 (en) 2021-04-12
CA2850296A1 (en) 2013-04-11
US10047116B2 (en) 2018-08-14
WO2013051994A1 (en) 2013-04-11
US20140234349A1 (en) 2014-08-21
US10487107B2 (en) 2019-11-26
EP3311827B1 (en) 2023-01-04
AU2012319239B2 (en) 2017-04-20
ES2673957T3 (en) 2018-06-26
AU2012319239A1 (en) 2014-04-03
ZA201402040B (en) 2016-01-27

Similar Documents

Publication Publication Date Title
AR095962A1 (en) NANOPARTICLES, STEROL AND SAPONINE COMPOUNDS OF QUILLAJA SAPONARIA MOLINA, PROCESS FOR PREPARATION AND USE OF THE SAME AS CARRIERS FOR AMPHIPATHIC OR HYDROPHOBLE MOLECULES IN THE FIELD OF THE MEDICINE INCLUDING CANCER TREATMENT AND COMPOUNDING
IN2014MN00948A (en)
PH12012502380B1 (en) Methods of treatment of pancreatic cancer
MX2020010535A (en) Methods of treating cancer.
WO2010132697A3 (en) Methods and compositions for treatment
IN2014MN00988A (en)
UA115983C2 (en) Dna-pk inhibitors
IN2014MN02069A (en)
PH12012501390A1 (en) Fatty acid fumarate derivatives and their uses
IN2014MN00987A (en)
EP2729180A4 (en) METAL-BISPHOSPHONATE NANOPARTICLES FOR CANCER THERAPY AND IMAGING AND TREATING BONE DISEASES
EP2576791B8 (en) Methods and compositions using listeria for adjuvant treatment of cancer
MX347471B (en) Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules.
IN2014MN00986A (en)
MX2013012458A (en) Intravascular delivery of nanoparticle compositions and uses thereof.
IN2014MN02049A (en)
NZ700759A (en) Combination therapy for treating cancer
IN2014KN00848A (en)
BR112012024442A2 (en) cancer treatment methods
BR112013000776A2 (en) Method and Formulation for Treatment of Sialic Acid Deficiency
MX2016008158A (en) Methods for shaping fibrous material and treatment compositions therefor.
MY165826A (en) Pharmaceutical composition
BRPI0914300B8 (en) vaccine for obesity treatment
MX363465B (en) Treatment of submental fat.
MX2012012095A (en) Thiazolidinedione analogues.